US5916891A
(en)
|
1992-01-13 |
1999-06-29 |
Smithkline Beecham Corporation |
Pyrimidinyl imidazoles
|
MX9705296A
(es)
*
|
1995-01-12 |
1997-10-31 |
Smithkline Beecham Corp |
Compuestos novedosos de imidazol 1,4,5-susbtituidos y el uso de los mismos para preparar composiciones para uso en terapia.
|
US5658903A
(en)
|
1995-06-07 |
1997-08-19 |
Smithkline Beecham Corporation |
Imidazole compounds, compositions and use
|
US6369068B1
(en)
|
1995-06-07 |
2002-04-09 |
Smithkline Beecham Corporation |
Amino substituted pyrimidine containing compounds
|
US5739143A
(en)
*
|
1995-06-07 |
1998-04-14 |
Smithkline Beecham Corporation |
Imidazole compounds and compositions
|
ZA9610687B
(en)
*
|
1995-12-22 |
1997-09-29 |
Smithkline Beecham Corp |
Novel synthesis.
|
US6046208A
(en)
*
|
1996-01-11 |
2000-04-04 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
ZA97175B
(en)
*
|
1996-01-11 |
1997-11-04 |
Smithkline Beecham Corp |
Novel substituted imidazole compounds.
|
NZ327044A
(en)
*
|
1996-01-11 |
2000-01-28 |
Smithkline Beecham Corp |
Substituted imidazole compounds
|
AP9700912A0
(en)
*
|
1996-01-11 |
1997-01-31 |
Smithkline Beecham Corp |
Novel cycloalkyl substituted imidazoles
|
US6372741B1
(en)
*
|
1996-03-08 |
2002-04-16 |
Smithkline Beecham Corporation |
Use of CSAID™ compounds as inhibitors of angiogenesis
|
US6235760B1
(en)
*
|
1996-03-25 |
2001-05-22 |
Smithkline Beecham Corporation |
Treatment for CNS injuries
|
JP2000507558A
(ja)
*
|
1996-03-25 |
2000-06-20 |
スミスクライン・ビーチャム・コーポレイション |
Cns損傷についての新規な治療
|
WO1998007425A1
(en)
|
1996-08-21 |
1998-02-26 |
Smithkline Beecham Corporation |
Imidazole compounds, compositions and use
|
AU5147598A
(en)
*
|
1996-10-17 |
1998-05-11 |
Smithkline Beecham Corporation |
Methods for reversibly inhibiting myelopoiesis in mammalian tissue
|
ZA9711092B
(en)
*
|
1996-12-11 |
1999-07-22 |
Smithkline Beecham Corp |
Novel compounds.
|
US6548512B1
(en)
|
1996-12-23 |
2003-04-15 |
Bristol-Myers Squibb Pharma Company |
Nitrogen containing heteroaromatics as factor Xa inhibitors
|
US6020357A
(en)
*
|
1996-12-23 |
2000-02-01 |
Dupont Pharmaceuticals Company |
Nitrogen containing heteroaromatics as factor Xa inhibitors
|
US5929076A
(en)
*
|
1997-01-10 |
1999-07-27 |
Smithkline Beecham Corporation |
Cycloalkyl substituted imidazoles
|
US6514977B1
(en)
|
1997-05-22 |
2003-02-04 |
G.D. Searle & Company |
Substituted pyrazoles as p38 kinase inhibitors
|
WO1998052941A1
(en)
*
|
1997-05-22 |
1998-11-26 |
G.D. Searle And Co. |
PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
|
US6979686B1
(en)
|
2001-12-07 |
2005-12-27 |
Pharmacia Corporation |
Substituted pyrazoles as p38 kinase inhibitors
|
JP2002504909A
(ja)
|
1997-06-13 |
2002-02-12 |
スミスクライン・ビーチャム・コーポレイション |
新規な置換ピラゾールおよびピラゾリン化合物
|
EP0994870A4
(de)
|
1997-06-19 |
2002-10-23 |
Smithkline Beecham |
Neue,durch einen aryloxyrest substituierte imidazolverbindungen
|
US6339099B1
(en)
|
1997-06-20 |
2002-01-15 |
Dupont Pharmaceuticals Company |
Guanidine mimics as factor Xa inhibitors
|
US7301021B2
(en)
|
1997-07-02 |
2007-11-27 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
TW517055B
(en)
|
1997-07-02 |
2003-01-11 |
Smithkline Beecham Corp |
Novel substituted imidazole compounds
|
US6489325B1
(en)
|
1998-07-01 |
2002-12-03 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
AR016294A1
(es)
*
|
1997-07-02 |
2001-07-04 |
Smithkline Beecham Corp |
Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
|
US6562832B1
(en)
|
1997-07-02 |
2003-05-13 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
WO1999001452A1
(en)
|
1997-07-02 |
1999-01-14 |
Smithkline Beecham Corporation |
Novel cycloalkyl substituted imidazoles
|
US6362193B1
(en)
|
1997-10-08 |
2002-03-26 |
Smithkline Beecham Corporation |
Cycloalkenyl substituted compounds
|
EP1021173A1
(de)
*
|
1997-10-10 |
2000-07-26 |
Imperial College Innovations Limited |
Verwendung von cytokin-unterdrückenden verbindungen (csaid) zur behandlung von gebärmutterkontraktionen
|
US6022884A
(en)
|
1997-11-07 |
2000-02-08 |
Amgen Inc. |
Substituted pyridine compounds and methods of use
|
HUP0004947A2
(hu)
*
|
1997-11-14 |
2002-03-28 |
Sankyo Co., Ltd. |
Piridilpirrol-származékok
|
WO1999032121A1
(en)
*
|
1997-12-19 |
1999-07-01 |
Smithkline Beecham Corporation |
Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
|
US7517880B2
(en)
*
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
US20080300281A1
(en)
*
|
1997-12-22 |
2008-12-04 |
Jacques Dumas |
Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
|
US6448257B1
(en)
|
1998-05-22 |
2002-09-10 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
US6340685B1
(en)
|
1998-05-22 |
2002-01-22 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
US6130235A
(en)
*
|
1998-05-22 |
2000-10-10 |
Scios Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
US6867209B1
(en)
|
1998-05-22 |
2005-03-15 |
Scios, Inc. |
Indole-type derivatives as inhibitors of p38 kinase
|
TR200003472T2
(tr)
|
1998-05-22 |
2001-09-21 |
Smithkline Beecham Corporation |
Yeni 2-alkil ikameli imidazol bileşikler
|
US6589954B1
(en)
|
1998-05-22 |
2003-07-08 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
US6858617B2
(en)
|
1998-05-26 |
2005-02-22 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
US6207687B1
(en)
*
|
1998-07-31 |
2001-03-27 |
Merck & Co., Inc. |
Substituted imidazoles having cytokine inhibitory activity
|
EP1112070B1
(de)
*
|
1998-08-20 |
2004-05-12 |
Smithkline Beecham Corporation |
Neue substituierte triazolverbindungen
|
AU772477B2
(en)
|
1998-08-28 |
2004-04-29 |
Scios Inc. |
Inhibitors of p38-alpha kinase
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
JP2002523498A
(ja)
|
1998-08-29 |
2002-07-30 |
アストラゼネカ・アクチエボラーグ |
ピリミジン化合物
|
DE69933680T2
(de)
|
1998-08-29 |
2007-08-23 |
Astrazeneca Ab |
Pyrimidine verbindungen
|
AU6476599A
(en)
*
|
1998-11-03 |
2000-05-22 |
Novartis Ag |
Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
|
AU1909200A
(en)
*
|
1998-11-04 |
2000-05-22 |
Smithkline Beecham Corporation |
Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
|
US6239279B1
(en)
|
1998-12-16 |
2001-05-29 |
Smithkline Beecham Corporation |
Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
|
GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
EP1140840B1
(de)
*
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
|
JP2002534468A
(ja)
|
1999-01-13 |
2002-10-15 |
バイエル コーポレイション |
p38キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
|
US7351834B1
(en)
|
1999-01-13 |
2008-04-01 |
Bayer Pharmaceuticals Corporation |
ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
EP1157026A1
(de)
|
1999-02-22 |
2001-11-28 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Polyheterocyclische verbindungen mit entzündungshemmender wirkung
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
DE60014603T2
(de)
|
1999-03-12 |
2006-02-16 |
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield |
Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
|
DE60023853T2
(de)
|
1999-03-12 |
2006-05-24 |
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield |
Aromatische heterozyklische verbindungen als antientzündungwirkstoffe
|
GB9907658D0
(en)
|
1999-04-06 |
1999-05-26 |
Zeneca Ltd |
Chemical compounds
|
CO5170501A1
(es)
*
|
1999-04-14 |
2002-06-27 |
Novartis Ag |
AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
|
US6930101B1
(en)
|
1999-05-17 |
2005-08-16 |
The Regents Of The University Of California |
Thiazolopyrimidines useful as TNFα inhibitors
|
IL146309A
(en)
|
1999-05-21 |
2008-03-20 |
Scios Inc |
Derivatives of the indole type and pharmaceutical preparations containing them as inhibitors of kinase p38
|
DE60024830T2
(de)
|
1999-07-09 |
2006-06-14 |
Boehringer Ingelheim Pharma |
Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
|
US7122666B2
(en)
*
|
1999-07-21 |
2006-10-17 |
Sankyo Company, Limited |
Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
|
GB9919778D0
(en)
*
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
US6541477B2
(en)
|
1999-08-27 |
2003-04-01 |
Scios, Inc. |
Inhibitors of p38-a kinase
|
WO2001019322A2
(en)
*
|
1999-09-17 |
2001-03-22 |
Smithkline Beecham Corporation |
Use of csaids in rhinovirus infection
|
ATE311385T1
(de)
*
|
1999-10-27 |
2005-12-15 |
Novartis Pharma Gmbh |
Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika
|
ATE305787T1
(de)
|
1999-11-23 |
2005-10-15 |
Smithkline Beecham Corp |
3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
|
US6759410B1
(en)
*
|
1999-11-23 |
2004-07-06 |
Smithline Beecham Corporation |
3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
|
DE60020595T2
(de)
*
|
1999-11-23 |
2006-03-16 |
Smithkline Beecham Corp. |
3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
|
AU1781601A
(en)
|
1999-11-23 |
2001-06-04 |
Smithkline Beecham Corporation |
3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
|
ES2236007T3
(es)
*
|
1999-12-08 |
2005-07-16 |
Pharmacia Corporation |
Composiciones de inhibidor de ciclooxigenasa-2 ue tiene un efecto terapeutico rapido.
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
US6608052B2
(en)
|
2000-02-16 |
2003-08-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as anti-inflammatory agents
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US7235551B2
(en)
*
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
MXPA02009460A
(es)
*
|
2000-03-30 |
2003-02-12 |
Shionogi & Co |
Nuevo proceso para producir derivados de imidazopiridina condensados y nuevas formas de cristales.
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
AU5754701A
(en)
*
|
2000-07-13 |
2002-01-30 |
Pharmacia Corp |
Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
|
PE20020506A1
(es)
*
|
2000-08-22 |
2002-07-09 |
Glaxo Group Ltd |
Derivados de pirazol fusionados como inhibidores de la proteina cinasa
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
CZ20031125A3
(cs)
*
|
2000-10-23 |
2003-10-15 |
Smithkline Beecham Corporation |
Nové sloučeniny
|
US6670357B2
(en)
*
|
2000-11-17 |
2003-12-30 |
Bristol-Myers Squibb Company |
Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
|
US6867300B2
(en)
*
|
2000-11-17 |
2005-03-15 |
Bristol-Myers Squibb Company |
Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
|
JP2004533989A
(ja)
|
2000-11-20 |
2004-11-11 |
サイオス インコーポレイテッド |
p38キナーゼのピペリジン/ピペラジン型阻害剤
|
CA2429382A1
(en)
*
|
2000-11-20 |
2002-06-06 |
Scios Inc. |
Indole-type inhibitors of p38 kinase
|
US6821966B2
(en)
|
2000-11-20 |
2004-11-23 |
Scios, Inc. |
Inhibitors of p38 kinase
|
US7115565B2
(en)
*
|
2001-01-18 |
2006-10-03 |
Pharmacia & Upjohn Company |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
|
US7199124B2
(en)
*
|
2001-02-02 |
2007-04-03 |
Takeda Pharmaceutical Company Limited |
JNK inhibitor
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
MXPA03008142A
(es)
*
|
2001-03-09 |
2003-12-12 |
Pfizer Prod Inc |
Nuevos compuestos antiinflamatorios de bencimidazol.
|
US7695736B2
(en)
|
2001-04-03 |
2010-04-13 |
Pfizer Inc. |
Reconstitutable parenteral composition
|
WO2002094267A1
(fr)
*
|
2001-05-24 |
2002-11-28 |
Sankyo Company, Limited |
Preparation pharmaceutique pour prevenir ou traiter l'arthrite
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
US7076539B2
(en)
*
|
2001-07-30 |
2006-07-11 |
Hewlett-Packard Development Company, L.P. |
Network connectivity establishment at user log-in
|
UA80682C2
(en)
*
|
2001-08-06 |
2007-10-25 |
Pharmacia Corp |
Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
|
GB0124931D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124934D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124938D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124933D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124936D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124941D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124932D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124939D0
(en)
*
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
HUP0401949A3
(en)
*
|
2001-10-22 |
2009-07-28 |
Mitsubishi Tanabe Pharma Corp |
4-imidazolin-2-one derivatives
|
DE60230907D1
(de)
*
|
2001-10-25 |
2009-03-05 |
Univ Connecticut |
Fibroinzusammensetzungen und verfahren zu deren herstellung
|
EP1439863B1
(de)
*
|
2001-10-29 |
2011-01-12 |
Boehringer Ingelheim International GmbH |
Mnk-kinase-homologe proteine, die an der regulierung der energiehomöostase und dem organellen metabolismus beteiligt sind
|
WO2003068229A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
EP2324825A1
(de)
|
2002-02-11 |
2011-05-25 |
Bayer Healthcare LLC |
Arylharnstoffe mit Angiogenese hemmender Aktivität
|
MXPA04007838A
(es)
|
2002-02-12 |
2004-10-15 |
Smithkline Beecham Corp |
Derivados de nicotamida utiles como inhibidores p38.
|
ATE386030T1
(de)
|
2002-02-25 |
2008-03-15 |
Boehringer Ingelheim Pharma |
1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
AU2003208479A1
(en)
|
2002-03-09 |
2003-09-22 |
Astrazeneca Ab |
4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
|
AR039241A1
(es)
*
|
2002-04-04 |
2005-02-16 |
Biogen Inc |
Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
|
EP2289894A3
(de)
|
2002-04-23 |
2011-07-20 |
Bristol-Myers Squibb Company |
Pyrrolo-triazine Verbindungen und deren verwendung als Kinase-inhibitoren
|
WO2004004725A2
(en)
|
2002-07-09 |
2004-01-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
|
GB0217757D0
(en)
|
2002-07-31 |
2002-09-11 |
Glaxo Group Ltd |
Novel compounds
|
EP1554272B1
(de)
|
2002-08-09 |
2006-10-25 |
Eli Lilly And Company |
Benzimidazole und benzothiazole als inhibitoren der map-kinase
|
US7268139B2
(en)
|
2002-08-29 |
2007-09-11 |
Scios, Inc. |
Methods of promoting osteogenesis
|
JP2006506346A
(ja)
|
2002-09-03 |
2006-02-23 |
サイオス インク. |
p38キナーゼ阻害剤としてのインドール系誘導体
|
UA80296C2
(en)
*
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Imidazolopyridines and methods of making and using the same
|
UA80295C2
(en)
*
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Pyrazolopyridines and using the same
|
EP1560582A4
(de)
|
2002-10-09 |
2008-03-12 |
Scios Inc |
AZAINDOL-DERIVATE ALS HEMMER DER p38 KINASE
|
CL2004000234A1
(es)
*
|
2003-02-12 |
2005-04-15 |
Biogen Idec Inc |
Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
|
US7557129B2
(en)
|
2003-02-28 |
2009-07-07 |
Bayer Healthcare Llc |
Cyanopyridine derivatives useful in the treatment of cancer and other disorders
|
GB0308185D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
GB0308186D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
GB0308201D0
(en)
*
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
GB0308466D0
(en)
*
|
2003-04-11 |
2003-05-21 |
Novartis Ag |
Organic compounds
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
ATE366108T1
(de)
|
2003-05-20 |
2007-07-15 |
Bayer Pharmaceuticals Corp |
Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
|
ATE439837T1
(de)
*
|
2003-06-03 |
2009-09-15 |
Novartis Ag |
5-gliedrige heterocyclische p-38 inhibitoren
|
TWI452035B
(zh)
|
2003-06-26 |
2014-09-11 |
Novartis Ag |
以5員雜環為主之p38激酶抑制劑
|
US7105467B2
(en)
*
|
2003-07-08 |
2006-09-12 |
Pharmacore, Inc. |
Nickel catalyzed cross-coupling reactions between organomagnesium compounds and anisole derivatives
|
NZ580384A
(en)
|
2003-07-23 |
2011-03-31 |
Bayer Pharmaceuticals Corp |
4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
|
CA2534990A1
(en)
*
|
2003-07-25 |
2005-02-10 |
Novartis Ag |
P-38 kinase inhibitors
|
GB0318814D0
(en)
*
|
2003-08-11 |
2003-09-10 |
Smithkline Beecham Corp |
Novel compounds
|
US7244441B2
(en)
|
2003-09-25 |
2007-07-17 |
Scios, Inc. |
Stents and intra-luminal prostheses containing map kinase inhibitors
|
WO2005032481A2
(en)
|
2003-09-30 |
2005-04-14 |
Scios Inc. |
Quinazoline derivatives as medicaments
|
US7419978B2
(en)
*
|
2003-10-22 |
2008-09-02 |
Bristol-Myers Squibb Company |
Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
|
US7880017B2
(en)
*
|
2003-11-11 |
2011-02-01 |
Allergan, Inc. |
Process for the synthesis of imidazoles
|
US7183305B2
(en)
*
|
2003-11-11 |
2007-02-27 |
Allergan, Inc. |
Process for the synthesis of imidazoles
|
US7105707B2
(en)
*
|
2003-12-17 |
2006-09-12 |
Pharmacore, Inc. |
Process for preparing alkynyl-substituted aromatic and heterocyclic compounds
|
GB0402143D0
(en)
*
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
MXPA06012512A
(es)
*
|
2004-04-28 |
2007-02-08 |
Tanabe Seiyaku Co |
Compuesto heterociclico.
|
TWI326282B
(en)
|
2004-04-28 |
2010-06-21 |
Mitsubishi Tanabe Pharma Corp |
Heterocyclic compound
|
JP2007535565A
(ja)
*
|
2004-04-30 |
2007-12-06 |
バイエル ファーマシューティカルス コーポレーション |
癌の治療に有用な置換ピラゾリル尿素誘導体
|
EP1768662A2
(de)
|
2004-06-24 |
2007-04-04 |
Novartis Vaccines and Diagnostics, Inc. |
Immunstimulatoren kleiner moleküle und assays für deren nachweis
|
US7504521B2
(en)
*
|
2004-08-05 |
2009-03-17 |
Bristol-Myers Squibb Co. |
Methods for the preparation of pyrrolotriazine compounds
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
US7148348B2
(en)
|
2004-08-12 |
2006-12-12 |
Bristol-Myers Squibb Company |
Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
|
US20080051416A1
(en)
*
|
2004-10-05 |
2008-02-28 |
Smithkline Beecham Corporation |
Novel Compounds
|
JP2006182763A
(ja)
*
|
2004-12-03 |
2006-07-13 |
Daiso Co Ltd |
α,β−不飽和エステルの製法
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
EP1676574A3
(de)
|
2004-12-30 |
2006-07-26 |
Johnson & Johnson Vision Care, Inc. |
Verfahren zur Förderung des Überlebens von Zell- und Gewebe-Transplantaten
|
US20060178388A1
(en)
*
|
2005-02-04 |
2006-08-10 |
Wrobleski Stephen T |
Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
|
GB0504753D0
(en)
*
|
2005-03-08 |
2005-04-13 |
Astrazeneca Ab |
Chemical compounds
|
PE20100737A1
(es)
|
2005-03-25 |
2010-11-27 |
Glaxo Group Ltd |
Nuevos compuestos
|
US7479558B2
(en)
*
|
2005-03-25 |
2009-01-20 |
Glaxo Group Limited |
Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
|
US20060235020A1
(en)
*
|
2005-04-18 |
2006-10-19 |
Soojin Kim |
Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
|
GB0512429D0
(en)
*
|
2005-06-17 |
2005-07-27 |
Smithkline Beecham Corp |
Novel compound
|
US7473784B2
(en)
*
|
2005-08-01 |
2009-01-06 |
Bristol-Myers Squibb Company |
Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
|
DE102005048072A1
(de)
*
|
2005-09-24 |
2007-04-05 |
Bayer Cropscience Ag |
Thiazole als Fungizide
|
UY29826A1
(es)
|
2005-09-30 |
2007-04-30 |
Astrazeneca Ab |
Derivados de pirimidina, sales farmaceuticamente aceptables, esteres de los mismos hidrolisables in vivo, procesos de preparacion y aplicaciones
|
DE102006001161A1
(de)
*
|
2006-01-06 |
2007-07-12 |
Qiagen Gmbh |
Verfahren zum Nachweis von Cytosin-Methylierungen
|
KR20080107408A
(ko)
*
|
2006-03-07 |
2008-12-10 |
브리스톨-마이어스 스큅 컴퍼니 |
키나제 억제제로서 유용한 피롤로트리아진 아닐린 전구약물화합물
|
KR20090004950A
(ko)
|
2006-04-12 |
2009-01-12 |
프로비오드룩 아게 |
효소 억제제
|
EP2468717B1
(de)
|
2006-10-27 |
2013-11-20 |
Bristol-Myers Squibb Company |
Heterocyclische Amidverbindungen als Kinasehemmer
|
US7943617B2
(en)
*
|
2006-11-27 |
2011-05-17 |
Bristol-Myers Squibb Company |
Heterobicyclic compounds useful as kinase inhibitors
|
EP1992344A1
(de)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
|
EP2300466B1
(de)
|
2008-06-20 |
2014-08-06 |
Bristol-Myers Squibb Company |
Imidazopyridin- und imidazopyrazinverbindungen als kinasehemmer
|
US8410128B2
(en)
*
|
2008-06-20 |
2013-04-02 |
Bristol-Myers Squibb Company |
Triazolopyridine compounds useful as kinase inhibitors
|
WO2012031057A1
(en)
|
2010-09-01 |
2012-03-08 |
Bristol-Myers Squibb Company |
Bms- 582949 for the treatment of resistant rheumatic disease
|
CN113350353A
(zh)
|
2015-03-23 |
2021-09-07 |
墨尔本大学 |
呼吸性疾病的治疗
|
AU2018262108A1
(en)
*
|
2017-05-03 |
2019-11-21 |
The University Of Melbourne |
Compounds for the treatment of respiratory diseases
|
CA3128468A1
(en)
|
2017-10-05 |
2019-04-11 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
WO2022195579A1
(en)
|
2021-03-15 |
2022-09-22 |
Saul Yedgar |
Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
|